Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an update.
Shanghai Henlius Biotech, Inc. successfully held its Annual General Meeting (AGM) on May 8, 2025, where all proposed resolutions were passed with significant shareholder support. The resolutions included the approval of the company’s annual report, board work report, board of supervisors’ work report, and final accounts report for the year 2024, reflecting strong operational performance and governance.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of biologic medicines. The company operates within the pharmaceutical industry, primarily offering products related to oncology and autoimmune diseases.
Average Trading Volume: 1,574,701
Technical Sentiment Signal: Buy
Current Market Cap: HK$20.14B
See more data about 2696 stock on TipRanks’ Stock Analysis page.